Erenumab in Chronic Migraine: An Australian Experience

Shuli Cheng, Bronwyn Jenkins, Nicole Limberg, Elspeth Hutton

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


Objective: To determine the effectiveness and safety of erenumab in patients with chronic migraine in the real-world setting of 3 headache centers in Australia. Methods: Patients with migraine were prescribed erenumab (70 or 140 mg) in the setting of either a product familiarization program or paid access to the medication in 3 headache centers in Australia. We obtained baseline and monthly prospective data on monthly headache days, monthly migraine days, monthly triptan use days, monthly codeine use days, Headache Impact Test-6 scores, and adverse reactions. In this paper, we present our data at 3 and 6 months in our subgroup of patients with chronic migraine with and without medication overuse. Results: A total of 170 patients with chronic migraine were prescribed erenumab in the 3 headache centers. At 3 months, 100/170 (58.8%) had 50% or greater reduction in monthly migraine days. At 6 months, 79/170 (46.5%) had 50% or greater reduction in monthly migraine days. At 6 months, there was a mean reduction in monthly headache days of 9.2 days, a mean reduction in monthly migraine days of 10.2 days. There were few adverse events reported. Conclusion: This is the first report from 3 Australian headache centers about erenumab in the real world. Our analysis has supported erenumab as an effective and well-tolerated migraine preventative therapy for patients with chronic migraine who have failed many preventative therapies.

Original languageEnglish
Pages (from-to)2555-2562
Number of pages8
Issue number10
Publication statusPublished - Nov 2020


  • Australia
  • calcitonin gene-related peptide monoclonal antibody
  • chronic migraine
  • erenumab

Cite this